- Spitfire List - http://spitfirelist.com -

FTR #912 Food for Thought

Dave Emory’s entire life­time of work is avail­able on a flash dri­ve that can be obtained here. [1] The new dri­ve is a 32-giga­byte dri­ve that is cur­rent as of the pro­grams and arti­cles post­ed by ear­ly win­ter of 2016. The new dri­ve (avail­able for a tax-deductible con­tri­bu­tion of $65.00 or more.)  (The pre­vi­ous flash dri­ve was cur­rent through the end of May of 2012.)

WFMU-FM is pod­cast­ing For The Record–You can sub­scribe to the pod­cast HERE [2].

You can sub­scribe to e‑mail alerts from Spitfirelist.com HERE [3]

You can sub­scribe to RSS feed from Spitfirelist.com HERE [4].

You can sub­scribe to the com­ments made on pro­grams and posts–an excel­lent source of infor­ma­tion in, and of, itself HERE [5].

This pro­gram was record­ed in one, 60-minute seg­ment [6].

The corporate logo of I.G. Farben. [7]

The cor­po­rate logo of I.G. Far­ben.

Martin Bormann (right) with Himmler [8]

Mar­tin Bor­mann (right) with Himm­ler

Intro­duc­tion: This pro­gram is spec­u­la­tive in nature, eval­u­at­ing the pos­si­bil­i­ty that com­pa­nies descend­ed from the I.G. Far­ben Ger­man chem­i­cal car­tel may absorb Mon­san­to, the firm not­ed for its devel­op­ment of genet­i­cal­ly mod­i­fied organ­isms.

Specif­i­cal­ly, Bay­er [9] and BASF [10] fig­ure in the report­ed maneu­ver­ing for Mon­san­to.

Against the back­ground of the remark­able Bor­mann cap­i­tal net­work’s [11]effec­tive con­trol of the firms that descend­ed from I.G. Far­ben, we rumi­nate about the pos­si­bil­i­ty of genet­i­cal­ly engi­neered bina­ry pathogens being includ­ed in the food sup­ply avail­able to much of the world’s pop­u­la­tion.

Avail­able infor­ma­tion high­lights pos­si­ble Under­ground Reich maneu­ver­ing to gain con­trol of firms mar­ket­ing food­stuffs to mid­dle, low­er mid­dle and work­ing class peo­ple. This spec­u­la­tion, in turn, is set against the back­ground of infor­ma­tion strong­ly sug­gest­ing that AIDS was delib­er­ate­ly devel­oped.

For more than three decades, Mr. Emory has pre­sent­ed pro­grams indi­cat­ing that AIDS [12] is a man-made dis­ease. Sup­ple­ment­ing that body of work, this pro­gram sets forth cir­cum­stan­tial evi­dence indi­cat­ing that AIDS may have been cre­at­ed on a foun­da­tion of research done by the Nazis in con­cen­tra­tion camps dur­ing the Sec­ond World War. Under a pro­gram named Project Paper­clip, Nazi scientists—many of them war criminals—were recruit­ed to do research for the U.S. nation­al secu­ri­ty estab­lish­ment.

Jorge Paulo Lemann [13]

Jorge Paulo Lemann

Recent med­ical research indi­cates the exis­tence of a genet­ic trait that affords immu­ni­ty to both AIDS and the infec­tions that have come to be known as “plague.” (Orig­i­nal­ly thought to be an out­break of bubon­ic plague–a bac­te­ri­o­log­i­cal disease–recent research has shift­ed focus to a viral dis­ease more akin to Ebo­la.)

This gene—the CCR5 delta-32 muta­tion [14]—is only car­ried by the white race and [accord­ing to some sources] only by peo­ple of North­ern Euro­pean extrac­tion. Did the Nazis note [in their exper­i­ments] that some peo­ple appeared to be immune to infec­tion with plague? Were tis­sue sam­ples tak­en and pre­served for fur­ther study? Was this in any way con­nect­ed to the even­tu­al evo­lu­tion of the CCR5-delta 32 gene as a hered­i­tary pro­tec­tion against infec­tion by HIV?

In June of 2009, it emerged [15] that CCR5 delta-32 was used in trans­plant ther­a­py admin­is­tered by a Ger­man doc­tor to an HIV-pos­i­tive leukemia patient. It appears that the patient was cured of HIV! The Ger­man doc­tor delib­er­ate­ly select­ed a CCR5 delta-32 pos­i­tive donor for the stem cells used for the trans­plant.

Obvi­ous­ly, we are won­der­ing about the pos­si­bil­i­ty of the Under­ground Reich using food­stuffs to vec­tor human­i­ty with genet­i­cal­ly engi­neered pathogens that will real­ize Hitler’s dream of an “Aryan” world.

Pro­gram High­lights Include:

1a. Bay­er may be poised to buy Mon­san­to.

“Bay­er Takeover of Mon­santo Would Cre­ate a Glob­al Giant” [AP]; The Los Ange­les Times; 5/19/2016. [9]

Bayer’s poten­tial acqui­si­tion of Mon­santo Co. would cre­ate a giant seed and farm chem­i­cal com­pany with a strong foot­print in the U.S., Europe and Asia, com­bin­ing two busi­nesses with com­ple­men­tary geo­graph­i­cal focus.

But Bay­er might have to shed part of its busi­ness because of antitrust con­cerns. [Con­sid­er that in light of the Bloomberg sto­ry about BASF–D.E.] And the price tag on any deal would be huge: Monsanto’s mar­ket val­ue is around $42 bil­lion.

Ger­many-based Bay­er said Thurs­day in a short state­ment that its exec­u­tives had met recent­ly with their Mon­santo coun­ter­parts “to pri­vately dis­cuss a nego­ti­ated acqui­si­tion” of the spe­cial­ist in genet­i­cally mod­i­fied crop seeds.

The news of a poten­tially cost­ly deal sent Bay­er shares tum­bling 8.2%. Mon­santo shares climbed 3.5%.

Both com­pa­nies are famil­iar brands on farms around the globe. Bay­er, whose farm busi­ness pro­duces seeds as well as com­pounds to kill weeds, bugs and fun­gus, said the pro­posed acqui­si­tion would help it “cre­ate a lead­ing inte­grated agri­cul­ture busi­ness.”

Mon­santo, based in St. Louis, said it was review­ing Bayer’s pro­posal. Nei­ther com­pany gave oth­er details.

The pos­si­ble deal had been rumored for a week, but these were the first com­ments from either com­pa­ny.

“A com­bi­na­tion of both com­pa­nies would cre­ate $67 bil­lion of annu­al sales and the world’s largest seed and crop-chem­i­cal com­pany,” ana­lyst Ulrich Huwald at War­burg Research wrote in a research note to investors. “How­ever, the ques­tion is if Mon­santo would be inter­ested in a deal.”

Huwald said that “the busi­nesses are geo­graph­i­cally com­ple­men­tary, with Mon­santo hav­ing a strong pres­ence in North Amer­ica and Bay­er in Europe and Asia.”

A com­bi­na­tion of the two would have 28% of the glob­al mar­ket for pes­ti­cides and a strong pres­ence in the U.S. corn and soy­bean seed busi­ness.

Huwald said that the two com­pa­nies do over­lap in their veg­etable and cot­ton seed busi­ness, which could require divest­ments due to antitrust issues. Bay­er might also have to sell parts of its weed killer busi­ness.

Antitrust reg­u­la­tors scru­ti­nize merg­ers and takeovers and have the author­ity to block them if they hin­der free-mar­ket com­pe­ti­tion. If com­pa­nies get too much con­trol over a mar­ket, they can charge high­er prices and have few­er incen­tives to inno­vate.

News of the talks fol­lows a wave of con­sol­i­da­tion in the chem­i­cal indus­try: DuPont and Dow Chem­i­cal agreed to com­bine last year, and Chem­China agreed to buy Syn­genta of Switzer­land in March after Monsanto’s own bid for its Basel-based rival failed. . . . .

1b. We note that BASF, like Bay­er, one of the suc­ces­sor com­pa­nies to I.G. Far­ben, has part­nered with Mon­san­to in many of their GMO projects. “ . . . . More­over, a Bay­er-Mon­san­to tie-up may put BASF’s col­lab­o­ra­tion with the Amer­i­cans at risk. BASF and Mon­santo work togeth­er on research and devel­op­ment in plant biotech­nol­ogy, giv­ing a strong rea­son, per­haps, to spoil Bayer’s plans. . . . ”

“BASF Best Leav­ing Mon­santo Seeds for the Birds” [17]by Olaf Stor­beck; Reuters; 5/19/2016. [17]

There is one thing the share­hold­ers of the chem­i­cal com­pany BASF should fear more than con­sol­i­da­tion between its Ger­man rival Bay­er and the Amer­i­can seed mak­er Mon­santo: their own board wad­ing in with a coun­ter­bid.

Bayer’s bid for Mon­santo puts BASF’s chief exec­u­tive, Kurt Bock, on the spot. With agri­cul­tural rev­enue of 5.8 bil­lion euros ($6.5 bil­lion), BASF is one of the world’s big play­ers in an indus­try where every­one seems to be enthu­si­as­ti­cally cou­pling. Think of Dow Chemical’s merg­er with DuPont, and Syngenta’s planned takeover by Chem­China. Only BASF would be left on the shelf.

More­over, a Bay­er-Mon­san­to tie-up may put BASF’s col­lab­o­ra­tion with the Amer­i­cans at risk. BASF and Mon­santo work togeth­er on research and devel­op­ment in plant biotech­nol­ogy, giv­ing a strong rea­son, per­haps, to spoil Bayer’s plans. . . .

1c. IF Bay­er does pur­chase Mon­san­to and is forced to divest itself of some sub­sidiary firms due to anti-trust con­sid­er­a­tions, BASF may well pick up those firms that are “spun off,” thus giv­ing the Under­ground Reich effec­tive con­trol of the GMO food busi­ness.

“. . . . In the lead up to Bay­er AG’s unso­licited takeover pro­posal for Mon­santo Co on Thurs­day, Chief Exec­u­tive Offi­cer Kurt Bock has talked up thrift, balk­ing at the price tags placed on assets. Rather than bet­ting the farm on a big deal and chal­leng­ing arch agro­chem­i­cals rival Bay­er for Mon­santo, Bock appears con­tent to stay out of the fray, ready to selec­tively buy up any busi­nesses that may come to the mar­ket in the dust of mega deals. . . .”

“BASF Is Sleep­ing Giant on Deals as Bay­er Moves on Mon­san­to” by Sheenagh Matthews and Andrew Marc Noel; Bloomberg; 5/19/2016. [10]

* Ger­man chem­i­cals mak­er fears over­pay­ing, los­ing inte­gra­tion
* CEO Kurt Bock may buy agro­chem­i­cals assets dis­carded on deals

With an aver­sion to over­pay­ing and con­vic­tion that a con­glom­er­ate approach is best, Germany’s BASF SE has so far sat out the biggest-ever con­sol­i­da­tion wave in the glob­al crop chem­i­cals and seeds indus­try.

In the lead up to Bay­er AG’s unso­licited takeover pro­posal for Mon­santo Co on Thurs­day, Chief Exec­u­tive Offi­cer Kurt Bock has talked up thrift, balk­ing at the price tags placed on assets. Rather than bet­ting the farm on a big deal and chal­leng­ing arch agro­chem­i­cals rival Bay­er for Mon­santo, Bock appears con­tent to stay out of the fray, ready to selec­tively buy up any busi­nesses that may come to the mar­ket in the dust of mega deals. . . . .

2. The I.G. Far­ben com­pa­ny, a core ele­ment of the Third Reich, was cen­tral to Reich­sleit­er Mar­tin Bormann’s plans to secret Germany’s wealth abroad. Note, also, I.G. Farben’s dom­i­nance of the Euro­pean chem­i­cal indus­try, and the opin­ion of Dr. von Schnit­zler that tech­ni­cal depen­dence on I.G. facil­i­ties would con­tin­ue after the war. (To learn more about I.G. Far­ben, see—among oth­er programs–FTR#’s 305 [18]411 [19]506 [20]552 [21]. Seri­ous stu­dents should also read Treason’s Peace [22] and The Devil’s Chemists [23], avail­able for down­load.)

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; p. 28. [11]

 . . . I.G. Far­ben was a for­mi­da­ble ally for Reich­sleit­er Bor­mann in his plans for the post­war eco­nom­ic rebirth of Ger­many. In a tele­phone con­ver­sa­tion with Dr. von Schnit­zler, Bor­mann asked what would the loss of fac­to­ries in France and the oth­er occu­pied coun­tries mean to Ger­man indus­try in gen­er­al and to I.G. in par­tic­u­lar. Dr. von Schnit­zler said he believed the tech­ni­cal depen­dence of these coun­tries on I.G. would be so great that despite Ger­man defeat I.G., in one way or anoth­er, could regain its posi­tion of con­trol of the Euro­pean chem­i­cal busi­ness. ‘They will need the con­stant tech­ni­cal help of I.G.’s sci­en­tif­ic lab­o­ra­to­ries as they do not own appro­pri­ate instal­la­tions with­in them­selves.’ . . . (Ibid.; p. 28.)

3. Bor­mann and Schmitz then dis­cussed I.G.’s prospects for the post­war peri­od. The cozy rela­tion­ship with pow­er­ful ele­ments with­in the pow­er elites of the West­ern allies was fore­seen by Schmitz as bod­ing well for the company’s future. Schmitz’s pre­dic­tions were rel­a­tive­ly accu­rate. Nei­ther Schmitz nor any of the I.G. Far­ben exec­u­tives were severe­ly pun­ished and the firm’s three suc­ces­sor firms car­ried on effec­tive­ly in the post­war peri­od.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; p. 158. [11]

. . . .The Reich­sleit­er asked Schmitz his views of the future. Schmitz replied, ‘The occu­pa­tion armies will be under­stand­ing in the West, but cer­tain­ly not in the East. I have instruct­ed all Far­ben admin­is­tra­tors and tech­ni­cians to come to the West, where they can be of use in resum­ing our oper­a­tions once the dis­tur­bances of 1945 come to a halt.’ Schmitz added that, while gen­er­al bomb dam­age to the I.G. plants was about 25 per­cent of capac­i­ty, some were untouched. He men­tioned speak­ing with Field Mar­shal Mod­el, who was com­mand­ing the defens­es of the Ruhr. ‘Mod­el had planned to turn our Bay­er-Leberkusen phar­ma­ceu­ti­cal fac­to­ry into an artillery base, but he agreed to make it an open, unde­fend­ed fac­to­ry. Hope­ful­ly, we will get it back untouched.’ ‘What about your board of direc­tors and the essen­tial exec­u­tives? If they are held by the occu­pa­tion author­i­ties, can I.G. con­tin­ue?’ Bor­mann asked. ‘We can con­tin­ue. We have an oper­a­tional plan for such a con­tin­gency, which every­one under­stands. How­ev­er, I don’t believe our board mem­bers will be detained too long. Nor will I. But we must go through a pro­ce­dure of inves­ti­ga­tion before release, so I have been told by our N.W. 7 peo­ple who have excel­lent con­tacts in Wash­ing­ton.’ . . .

4. The broad­cast details the pro­found rela­tion­ship between I.G. Far­ben and the gov­ern­ment of the Third Reich. Of par­tic­u­lar util­i­ty to the Bor­mann flight cap­i­tal pro­gram was I.G. Farben’s elab­o­rate infra­struc­ture in for­eign coun­tries. Note that, as is seen here, I.G. Far­ben was inex­tri­ca­bly linked with both the gov­ern­ment of the Third Reich and with the Nazi par­ty itself. Of par­tic­u­lar sig­nif­i­cance is the N.W.7 office and its con­trol by Mar­tin Bor­mann.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; p. 54. [11]

 . . . This, too, report­ed to Mar­tin Bormann.I.G. Farben’s N.W.7 office in Berlin com­piled mil­i­tary and eco­nom­ic data on all coun­tries for the Wehrma­cht. This depart­ment was staffed with men of rec­og­nized abil­i­ty in all branch­es of busi­ness and sci­ence. It was under the direc­tion of Dr. Max Ilgn­er, nephew of Her­mann Schmitz, I.G.’s pres­i­dent, who was known through­out the indus­tri­al world as ‘the mas­ter of finan­cial cam­ou­flage.’ [Empha­sis added.] Far­ben had offices and rep­re­sen­ta­tives in 93 coun­tries, and no social gath­er­ing of busi­ness­men was too small to be cov­ered by an N.W.7 rep­re­sen­ta­tive, whose reports on mar­ket con­di­tions, fac­to­ry instal­la­tions, raw-mate­r­i­al sup­plies, and research were trans­mit­ted imme­di­ate­ly to Berlin and Dr. Ilgn­er. In the Unit­ed States, N.W.7 oper­at­ed through the firm of Chem­ny­co, Inc., an Amer­i­can-formed sub­sidiary. Chem­ny­co sent tremen­dous amounts of infor­ma­tion rang­ing from pho­tographs and blue prints to detailed descrip­tions of entire indus­tri­al com­plex­es and secret process­es. . . .”

5. Of par­tic­u­lar impor­tance for this dis­cus­sion is the fact that I.G. used Ger­man mil­i­tary con­quest to gain effec­tive func­tion­al con­trol of the chem­i­cal indus­try of the con­ti­nent. In para­graph 13, we not­ed Georg von Scnitzler’s pre­dic­tion that I.G.’s tech­ni­cal dom­i­nance would result in the post­war per­pet­u­a­tion of this con­trol. As we will see, this con­trol was main­tained. Note the role of the N.W.7 Far­ben espi­onage orga­ni­za­tion in Bor­man­n’s plans for the secret­ing of Nazi monies abroad.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; pp. 55–58. [11]

. . . This huge orga­ni­za­tion func­tioned as a man­u­fac­tur­ing and research arm of the Ger­man gov­ern­ment, with the respon­si­bil­i­ty of dis­cov­er­ing all pos­si­ble means of increas­ing the mil­i­tary pow­er of Ger­many. More than RM 4.25 bil­lion was invest­ed in new plants, mines, and pow­er instal­la­tions, with oth­er mil­lions going into new research facil­i­ties. . . . So close had Far­ben become to the gov­ern­ment that I.G. always knew in advance all inva­sions planned by Hitler. It was to sup­ply the mate­ri­als nec­es­sary to each con­quest, and when a land had been over­run and sub­ju­gat­ed, the Far­ben experts would han­dle the con­sol­i­da­tion and orga­ni­za­tion of the indus­tri­al facil­i­ties as addi­tion­al sup­ply sources for the Ger­man armed forces. As Ger­man troops swept across Europe and Hitler pro­claimed his vision of a thou­sand-year Third Reich, I.G. Far­ben also dreamed of world empire. This was out­lined with clar­i­ty in a doc­u­ment called Neuord­nung, or ‘New Order,’ that was accom­pa­nied by a let­ter of trans­mit­tal to the Min­istry of Eco­nom­ics. It declared that a new order for the chem­i­cal indus­try of the world should sup­ple­ment Hitler’s New Order. There­fore, the doc­u­ment stat­ed, Far­ben was fit­ting future indus­tri­al plans into such a frame­work. . . . I.G. Far­ben was the major chem­i­cal firm on the Con­ti­nent, and as each coun­try fell to Ger­many its acqui­si­tions of chem­i­cal and dyestuff com­pa­nies were enor­mous. I.G. also increased its invest­ments in these by RM 7 bil­lion. [Empha­sis added.]

. . . .The close rela­tion­ship of Far­ben to the Third Reich lead­er­ship was under­scored in oth­er ways. I.G.’s lead­ing offi­cials assist­ed in the for­mu­la­tion and exe­cu­tion of eco­nom­ic poli­cies of gov­ern­ment; its pres­i­dent was a mem­ber of the Reich­stag; its lead­ing sci­en­tist was a chief assis­tant to Her­mann Goer­ing under the Four-Year Plan; its sta­tis­ti­cians and econ­o­mists pre­pared intel­li­gence for the Nazi High Com­mand; scores of its tech­ni­cians were at any giv­en time on loan to the air and war min­istries.

. . . The con­tact men of N.W.7 through­out the world were called the I.G. Verbindungs­man­ner, the liai­son offi­cers between Far­ben back in Ger­many and the branch­es else­where. These I.G. Verbindungs­man­ner, as well as all oth­er key Far­ben rep­re­sen­ta­tives work­ing beyond the bor­ders of the Third Reich, were mem­bers of the Nation­al Social­ist Ger­man Work­ers Par­ty. . . . So now Mar­tin Bor­mann had at his com­mand not only the Aus­lands-Organ­i­sa­tion but also the I.G. Verbindungs­man­ner of Far­ben, which could be count­ed on to heed his orders when it was time to dis­perse the com­mer­cial assets of the Third Reich. . . .

6. More about how the vast inter­na­tion­al oper­a­tions of the I.G. Far­ben firm and its var­i­ous sub­sidiary oper­a­tions was a prin­ci­pal ele­ment of the Bor­mann orga­ni­za­tion. I.G. Far­ben chief Her­mann Schmitz dis­cussed I.G.’s involve­ment with the Bor­mann pro­gram.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; pp. 157–158. [11]

. . . . In tes­ti­mo­ny lat­er giv­en to Nurem­berg inves­ti­ga­tors, Schmitz praised Bor­mann for the way he had direct­ed the dis­tri­b­u­tion of Ger­man assets around the world. His own Far­ben orga­ni­za­tion had, of course, con­tributed to the suc­cess of the oper­a­tion. Every region­al rep­re­sen­ta­tive work­ing for Her­mann Schmitz was an excep­tion­al busi­ness­man, or he would not have been with I.G. All had con­tributed sound advice in their areas of com­pe­tence, the regions of the world where they rep­re­sent­ed Far­ben while keep­ing an eye on the sub­sidiaries of the par­ent con­cern and the 700 hid­den cor­po­ra­tions they con­trolled. They had pro­vid­ed assis­tance and con­tin­u­ing guid­ance in estab­lish­ing the 750 new com­pa­nies cre­at­ed on order of Bor­mann, who want­ed more than hid­den assets; Bor­mann want­ed the mon­ey and patents and tech­ni­cians put to work to cre­ate even greater assets that would bol­ster Ger­many in the post­war years. In their meet­ing in the chan­cellery, both men checked over the fig­ures of sums dis­bursed, and they were accu­rate to the pfen­nig. . . .

7. As fore­cast by Dr. Scheid in the August 10, 1944 meet­ing, the cor­po­rate allies of the major Ger­man cor­po­ra­tions, includ­ing and espe­cial­ly those of I.G. Far­ben, proved to be of great val­ue to the uccess of the Bor­mann flight cap­i­tal pro­gram.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; p. 156. [11]

. . . . Pow­er­ful friends of the Bor­mann orga­ni­za­tion in all West­ern coun­tries, includ­ing those sprin­kled in con­trol points through­out the admin­is­tra­tion in Wash­ing­ton and in the finan­cial and bro­ker­age busi­ness­es of Wall Street, the City of Lon­don, and the Paris estab­lish­ment, did not wish a coor­di­nat­ed dri­ve to get at these exter­nal Ger­man assets. They had under­stand­able rea­sons, if you over­look moral­i­ty: the finan­cial ben­e­fits for coop­er­a­tion (col­lab­o­ra­tion had become an old-hat term with the war wind­ing down) were very entic­ing, depend­ing on one’s impor­tance and abil­i­ty to be of ser­vice to the orga­ni­za­tion and the 750 cor­po­ra­tions they were secret­ly manip­u­lat­ing, to say noth­ing of the known multi­na­tion­als such as I.G. Far­ben, Thyssen A.G., and Siemens; and, as a sec­ond rea­son, the phi­los­o­phy of free enter­prise and preser­va­tion of pri­vate prop­er­ty. . . . (Ibid.; p. 156.)

8. Note the post­war resus­ci­ta­tion of I.G. Far­ben, in the form of the “Big Three” suc­ces­sor firms that grew out Far­ben. Although offi­cial­ly bro­ken up at the end of World War II, I.G. Far­ben con­tin­ued func­tion­ing in new form. Recent merg­ers (such as the 1996 merg­er of I.G. car­tel affil­i­ates Ciba-Geigy and San­doz to form Novar­tis) indi­cate a new com­ing togeth­er of the old com­po­nents of I.G. Again, pay close atten­tion to the rela­tion­ship between these com­pa­nies and the Bor­mann cap­i­tal net­work.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; p. 282. [11]

. . . . By 1956, the three major multi­na­tion­als (Hoechst, BASF, and Bay­er) reshaped from the 159 com­pa­nies with­in Ger­many that had com­prised I.G. Far­ben were gen­er­at­ing record prof­its for the orig­i­nal 450 major Far­ben stock­hold­ers, who had orga­nized them­selves into the I.G. Far­ben Stock­hold­ers Pro­tec­tive com­mit­tee in Bonn. The Big Three went on expand­ing, tripling cap­i­tal­iza­tion in 1956 from invest­ment funds that poured in from the inter­lock­ing com­pa­nies estab­lished in safe haven coun­tries by Mar­tin Bor­mann and Her­mann Schmitz. There was a return, more vig­or­ous than ever, of the huge, mono­lith­ic indus­tri­al multi­na­tion­als that dom­i­nat­ed the Ger­man econ­o­my before and dur­ing World War II. . . .

9. The enor­mous cor­po­rate wealth and pow­er of the three suc­ces­sor firms is at the dis­pos­al of the Bor­mann cap­i­tal net­work and Under­ground Reich.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; pp. 282–283. [11]

. . . . Each of these three spin­offs from I.G. Far­ben today does more busi­ness indi­vid­u­al­ly than did Far­ben at its zenith, when its cor­po­rate struc­ture cov­ered 93 coun­tries. BASF and Bay­er indi­vid­u­al­ly boast world­wide sales of near­ly $10 bil­lion annu­al­ly, while Hoechst, now the world’s largest chem­i­cal com­pa­ny, gen­er­at­ed $16.01 bil­lion in world­wide sales in 1980. Each does more busi­ness than E.I. du Pont de Nemours, with sales of $9.4 bil­lion. The Unit­ed States is, of course, the major mar­ket, one into which these Ger­man cor­po­ra­tions con­tin­ue to pour invest­ment mon­ey for both new cap­i­tal con­struc­tion and cor­po­rate takeovers. Togeth­er, these three multi­na­tion­als assure per­ma­nent pros­per­i­ty for the orig­i­nal 450 Far­ben stock­hold­ers, their banks, and the shad­owy share­hold­ers of the Bor­mann orga­ni­za­tion in South Amer­i­ca who guard and vote the Her­mann Schmitz trust fund through inter­me­di­aries at the annu­al meet­ings of BASF, Bay­er and Hoechst. [Empha­sis added.] . . . .

10. A sig­nif­i­cant part of the I.G. Far­ben lega­cy, the Her­mann Schmitz Trust is also at the dis­pos­al of the Bor­mann cap­i­tal net­work and the Under­ground Reich.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; pp. 279–280. [11]

. . . . If there is any doubt in Europe who, in the long run, won the peace, there is none what­so­ev­er among the for­mer Ger­man lead­ers dwelling in South Amer­i­ca. It is a good bet that if Her­mann Schmitz were alive today, he would bear wit­ness as to who real­ly won. Schmitz died con­tent­ed, hav­ing wit­nessed the resur­gence of I.G. Far­ben, albeit in altered cor­po­rate forms, a mon­ey machine that con­tin­ues to gen­er­ate prof­its for all the old I.G. share­hold­ers and enor­mous inter­na­tion­al pow­er for the Ger­man cadre direct­ing the work­ings of the suc­ces­sor firms. . . . He was the mas­ter manip­u­la­tor, the cor­po­rate and finan­cial wiz­ard, the magi­cian, who could make mon­ey appear and dis­ap­pear, and reap­pear again. His whole exis­tence was leg­erde­main, played out on the game­board of I.G. Far­ben and his beloved Ger­many. . . Their [Schmitz and Bor­mann] asso­ci­a­tion was close and trust­ing over the years, and it is the con­sid­ered opin­ion of those in their cir­cle that the wealth pos­sessed by Her­mann Schmitz was shift­ed to Switzer­land and South Amer­i­ca, and placed in trust with Bor­mann, the legal heir to Hitler. [Her­mann] Schmitz’s wealth—largely I.G. Far­ben bear­er bonds con­vert­ed to the Big Three suc­ces­sor firms, shares in Stan­dard Oil of New Jer­sey (equal to those held by the Rock­e­fellers), as well as shares in the 750 cor­po­ra­tions he helped Bor­mann estab­lish dur­ing the last year of World War II—has increased in all seg­ments of the mod­ern indus­tri­al world. The Bor­mann orga­ni­za­tion in South Amer­i­ca uti­lizes the vot­ing pow­er of the Schmitz trust along with their own assets to guide the multi­na­tion­als they con­trol, as they keep steady the eco­nom­ic course of the Father­land. . . .

11. The pro­gram notes the eco­nom­ic and polit­i­cal sig­nif­i­cance of the Bor­mann net­work:

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; pp. 284–285. [11]

. . . . Atop an orga­ni­za­tion­al pyra­mid that dom­i­nates the indus­try of West Ger­many through banks, vot­ing rights enjoyed by major­i­ty share­hold­ers in sig­nif­i­cant car­tels, and the pro­fes­sion­al input of a rel­a­tive­ly young lead­er­ship group of lawyers, invest­ment spe­cial­ists, bankers, and indus­tri­al­ists, he is sat­is­fied that he achieved his aim of help­ing the Father­land back on its feet. To ensure con­ti­nu­ity of pur­pose and direc­tion, a close watch is main­tained on the prof­it state­ments and man­age­ment reports of cor­po­ra­tions under its con­trol else­where. This lead­er­ship group of twen­ty, which is in fact a board of direc­tors, is chaired by Bor­mann, but pow­er has shift­ed to the younger men who will car­ry on the ini­tia­tive that grew from that his­toric meet­ing in Stras­bourg on August 10, 1944. Old Hein­rich Mueller, chief of secu­ri­ty for the NSDAP in South Amer­i­ca, is the most feared of all, hav­ing the pow­er of life and death over those deemed not to be act­ing in the best inter­ests of the orga­ni­za­tion. Some still envi­sion a Fourth Reich. . .What will not pass is the eco­nom­ic influ­ences of the Bor­mann orga­ni­za­tion, whose com­mer­cial direc­tives are obeyed almost with­out ques­tion by the high­est ech­e­lons of West Ger­man finance and indus­try. ‘All orders come from the share­hold­ers in South Amer­i­ca,’ I have been told by a spokesman for Mar­tin Bor­mann. . . . .(Ibid.; pp. 284–5.)

13. Next, we review an excerpt from FTR #305 [18], highlighting–among oth­er things–Becker GMBH. The firm, found­ed by an SS vet­er­an of the “Final Solu­tion” with mon­ey tak­en from Jew­ish vic­tims of the con­cen­tra­tion camps, was absorbed into ConA­gra, a major pro­duc­er of food­stuffs mar­ket­ed to mid­dle, low­er-mid­dle and work­ing-class peo­ple. The Bor­mann group would undoubt­ed­ly have received stock options and/or a seat on the board of direc­tors. Thus, the Under­ground Reich would have direct influ­ence in a major pro­duc­er of food­stuffs for work­ing peo­ple.

“Nazi Mon­ey Trail Heats Up after 50 Years” by Greg Stein­metz; Wall Street Jour­nal; 4/28/97; p. A1.

14a. Next, we present an excerpt from FTR #606 [24] about the “Aryan Gene” that pro­vides immu­ni­ty to HIV infec­tion.

The pro­gram reviews an excerpt from tes­ti­mo­ny before a House appro­pri­a­tions sub­com­mit­tee that was draw­ing up the defense bud­get for the fol­low­ing year. (The hear­ings were in 1969.) The tes­ti­mo­ny dis­cuss­es the pos­si­bil­i­ty of using genet­ic engi­neer­ing to pro­duce a dis­ease that would be “refrac­to­ry” to the immune sys­tem. This is vir­tu­al­ly the clin­i­cal def­i­n­i­tion of AIDS. It is worth not­ing that the project was fund­ed, and just such a disease—AIDS—appeared in just the time frame posit­ed. It is also worth not­ing that, in the 2002 edi­tion of A High­er Form of Killing, this pas­sage is omit­ted!!

A High­er Form of Killing; Robert Har­ris and Jere­my Pax­man; Hill and Wang [SC]; ISBN 0–8090-5471‑X; p. 241 (p. 266 in e‑book). [12]

. . . As long ago as 1962, forty sci­en­tists were employed at the U.S. Army bio­log­i­cal war­fare lab­o­ra­to­ries on full-time genet­ics research. ‘Many oth­ers,’ it was said, ‘appre­ci­ate the impli­ca­tions of genet­ics for their own work.’ The impli­ca­tions were made more spe­cif­ic that genet­ic engi­neer­ing could solve one of the major dis­ad­van­tages of bio­log­i­cal war­fare, that it is lim­it­ed to dis­eases which occur nat­u­ral­ly some­where in the world. ‘With­in the next 5 to 10 years, it would prob­a­bly be pos­si­ble to make a new infec­tive micro-organ­ism which could dif­fer in cer­tain impor­tant respects from any known dis­ease-caus­ing organ­isms. Most impor­tant of these is that it might be refrac­to­ry to the immuno­log­i­cal and ther­a­peu­tic process­es upon which we depend to main­tain our rel­a­tive free­dom from infec­tious dis­ease.’ [Ital­ics are Mr. Emory’s.] The pos­si­bil­i­ty that such a ‘super germ’ may have been suc­cess­ful­ly pro­duced in a lab­o­ra­to­ry some­where in the world in the years since that assess­ment was made is one which should not be too read­i­ly cast aside. . . .

14b. Next, the pro­gram reviews dis­cus­sion of the gene pro­vid­ing peo­ple of the white race [and—according to some sources—primarily those of North­ern Euro­pean extrac­tion] with immu­ni­ty from the AIDS virus. The pro­gram high­lights that gene’s role in pro­vid­ing some peo­ple with immu­ni­ty from the plagues that rav­aged Europe cen­turies ago. (The gene is CCR5 delta32.)

Note that no oth­er eth­nic groups or races have the delta 32 gene that pre­vents infec­tion by HIV.

 “Secrets of the Dead—Case File: Mys­tery of the Black Death; Back­ground”; Secrets of the Dead. [14]

. . . In Sep­tem­ber 1665, George Vic­cars, a tai­lor in the small, cen­tral-Eng­land vil­lage of Eyam, received a par­cel of cloth rid­den with plague-infect­ed fleas from Lon­don. Four days lat­er, Vic­cars died. By the end of the month, five more vil­lagers had suc­cumbed to the plague. The pan­icked town turned to their rec­tor, William Mom­pes­son, who per­suad­ed them to quar­an­tine the entire vil­lage to pre­vent the bac­teri­um from spread­ing through­out the region. It seemed like sui­cide. A year lat­er, the first out­siders ven­tured into Eyam, expect­ing a ghost town. Yet, mirac­u­lous­ly, half the town had sur­vived. How did so many vil­lagers live through the most dev­as­tat­ing dis­ease known to man? . . .

Local Eyam lore tells befud­dling sto­ries of plague sur­vivors who had close con­tact with the bac­teri­um but nev­er caught the dis­ease. Eliz­a­beth Han­cock buried six chil­dren and her hus­band in a week, but nev­er became ill. The vil­lage gravedig­ger han­dled hun­dreds of plague-rav­aged corpses, but sur­vived as well. Could these peo­ple have some­how been immune to the Black Death?”

Dr. Stephen O’Brien of the Nation­al Insti­tutes of Health in Wash­ing­ton D.C. sug­gests they were. His work with HIV and the mutat­ed form of the gene CCR, called ‘delta 32,’ led him to Eyam. In 1996, research showed that delta32 pre­vents HIV from enter­ing human cells and infect­ing the body. O’Brien thought this prin­ci­ple could be applied to the plague bac­te­ria, which affects the body in a sim­i­lar man­ner. To deter­mine whether the Eyam plague sur­vivors may have car­ried delta 32, O’Brien test­ed the DNA of their mod­ern-day descen­dents. What he found out was star­tling . . .”

For a dis­ease-caus­ing microor­gan­ism to infect the human body there must be a gate­way or por­tal through which it enters into human cells. The plague bac­teri­um works this way, hijack­ing the white blood cells sent to elim­i­nate it. Trav­el­ing inside the white blood cells to the lymph nodes, the bac­te­ria break out and attack the focal point of the human immune sys­tem. Dr. Stephen O’Brien felt that the mutat­ed CCR5 gene, delta 32, may have pre­vent­ed the plague from being able to enter its host’s white blood cells.

Eyam pro­vid­ed O’Brien an ide­al oppor­tu­ni­ty to test this the­o­ry. Specif­i­cal­ly, Eyam was an iso­lat­ed pop­u­la­tion known to have sur­vived a plague epi­dem­ic. Every­one in the town would have been exposed to the bac­teri­um, so it’s like­ly that any life-sav­ing genet­ic trait would have been exposed to the bac­teri­um, so it’s like­ly that any life-sav­ing genet­ic trait would have been pos­sessed by each of these sur­vivors. ‘Like a Xerox machine,’ says O’Brien, ‘their gene fre­quen­cies have been repli­cat­ed for sev­er­al gen­er­a­tions with­out a lot of infu­sion from out­side,’ thus pro­vid­ing a viable pool of sur­vivor-descen­dants who would have inher­it­ed such a trait. . . .

. . . DNA sam­ples could only be col­lect­ed from direct descen­dents of the plague sur­vivors. DNA is the prin­ci­ple com­po­nent of chro­mo­somes, which car­ry the genes that trans­mit hered­i­tary char­ac­ter­is­tics. We inher­it our DNA from our par­ents, thus Eyam res­i­dent Joan Plant, for instance, may have inher­it­ed the delta 32 muta­tion from one of her ancient rel­a­tives. Plant can trace her mother’s lin­eage back ten gen­er­a­tions to the Black­well sib­lings, Fran­cis and Mar­garet, who both lived through the plague to the turn of the cen­tu­ry. The next step was to har­vest a DNA sam­ple from Joan and the oth­er descen­dants. DNA is found in the nuclei of cells. The amount is con­stant in all typ­i­cal cells, regard­less of the size or func­tion of that cell. One of the eas­i­est meth­ods of obtain­ing a DNA tis­sue sam­ple is to take a cheek or buc­cal swab. . . .

After three weeks of test­ing at Uni­ver­si­ty Col­lege in Lon­don, delta 32 had been found in 14% of the sam­ples. This is a genet­i­cal­ly sig­nif­i­cant per­cent­age, yet what, real­ly, did it mean? Could the vil­lagers have inher­it­ed delta 32 from else­where, res­i­dents who had moved to the com­mu­ni­ty in the 350 years since the plague? Was this real­ly a high­er per­cent­age than any­where else? To find out, O’Brien assem­bled an inter­na­tion­al team of sci­en­tists to test for the pres­ence of delta 32 around the world. ‘Native Africans did not have delta 32 at all,’ O’Brien says, ‘and when we looked at East Asians and Indi­ans, they were also flat zero.’ In fact the lev­els of delta 32 found in Eyam were only matched in regions of Europe that had been affect­ed by the plague and in Amer­i­ca, which was, for the most part, set­tled by Euro­pean plague sur­vivors and their descen­dants.”

Mean­while, recent work with anoth­er dis­ease strik­ing­ly sim­i­lar to the plague, AIDS, sug­gests O’Brien was on the right track. HIV, the virus that caus­es AIDS, tricks the immune sys­tem in a sim­i­lar man­ner as the plague bac­teri­um, tar­get­ing and tak­ing over white blood cells. Virol­o­gist Dr. Bill Pax­ton at the Aaron Dia­mond AIDS Research Cen­ter in New York City noticed, ‘the cen­ter had no study of peo­ple who were exposed to HIV but who had remained neg­a­tive.’ He began test­ing the blood of high-risk, HIV-neg­a­tive indi­vid­u­als like Steve Crohn, expos­ing their blood to three thou­sand times the amount of HIV nor­mal­ly need­ed to infect a cell. Steve’s blood nev­er became infect­ed. ‘We thought maybe we had infect­ed the cul­ture with bac­te­ria or what­ev­er,’ says Pax­ton. ‘So we went back to Steve. But it was the same result. We went back again and again. Same result.’ Pax­ton began study­ing Crohn’s DNA, and con­clud­ed there was some sort of block­ing mech­a­nism pre­vent­ing the virus from bind­ing to his cells. Fur­ther research showed that that mech­a­nism was delta 32. Sci­en­tists study­ing HIV first learned about the gate­way-block­ing capac­i­ty of the CCR5 muta­tion in 1996. Sev­er­al drug com­pa­nies, then, quick­ly began explor­ing the pos­si­bil­i­ty of devel­op­ing phar­ma­ceu­ti­cals that would mim­ic delta 32 by bind­ing to CCR5 and block­ing the attach­ment of HIV. . . .

14c. In June of 2009, it emerged that CCR5 delta-32 was used in trans­plant ther­a­py admin­is­tered by a Ger­man doc­tor to an HIV-pos­i­tive leukemia patient. It appears that the patient was cured of HIV! The Ger­man doc­tor delib­er­ate­ly select­ed a CCR5 delta-32 pos­i­tive donor for the stem cells used for the trans­plant. Dr. Gup­ta, quot­ed in the fol­low­ing arti­cle, won­ders why more pub­lic­i­ty was­n’t afford­ed this event. Why indeed?

“Local Physician:HIV/AIDS Cure Get­ting Lit­tle Pub­lic­i­ty” by Bob Mor­gan; Gulf Coast News Today; 5/27/2009. [15]

A Foley [Alaba­ma] physi­cian said what appears to be the first case of HIV/AIDS cure in the world is get­ting lit­tle men­tion in the media.

Dr. Awad­hesh K. Gup­ta, med­ical direc­tor at Foley Walk-In Med Care, said he first heard of the med­ical break­through in April when he attend­ed the Annu­al Con­fer­ence of the Amer­i­can Col­lege of Physi­cians in Inter­nal Med­i­cine in Philadel­phia.

It’s a con­fer­ence Gup­ta tries to attend every year.

“This is the most pres­ti­gious orga­ni­za­tion of physi­cians in Inter­nal Med­i­cine and is respon­si­ble for cer­ti­fy­ing post grad­u­ate train­ing in Inter­nal Med­i­cine. It is also one of the old­est,” he said.

Accord­ing to Gup­ta, who has been prac­tic­ing med­i­cine in the South Bald­win area since 1997, the cure was first report­ed in ear­ly 2008 by a group of physi­cians from Ger­many at the annu­al con­fer­ence on “Retro­virus­es and Oppor­tunis­tic Infec­tions” in Boston. The New Eng­land Jour­nal of Med­i­cine, one of the most pres­ti­gious med­ical jour­nals in the world, final­ly pub­lished the report in its Feb. 12, 2009, issue, Gup­ta said.

So why has the news of the first case of HIV/AIDS cure received so lit­tle atten­tion where the pub­lic is con­cerned?

“I can’t be sure as to why so lit­tle pub­lic­i­ty,” Gup­ta said recent­ly.

“My guess is that most sci­en­tif­ic researchers are some­what stunned that a clin­i­cian — not a research sci­en­tist — has been able to come up with the cure. Most of the big research mon­ey and big name Amer­i­can insti­tu­tions are some­what embar­rassed to acknowl­edge that the very first case of HIV cure is not com­ing from their insti­tu­tions.”

The cure, instead, is com­ing from Char­i­ty Uni­ver­si­ty Hos­pi­tal in Berlin, Ger­many, and the doc­tor is Gero Huet­ter, who works in the Depart­ment of Hema­tol­ogy, Oncol­o­gy and Trans­fu­sion Med­i­cine at the same hos­pi­tal.

Asked about the reac­tion of atten­dees at the med­ical con­fer­ence in Philadel­phia as regard­ed the news of an HIV/AIDS cure, Gup­ta said, “Unfor­tu­nate­ly, because of the hec­tic sched­ule, I did not try to engage too many physi­cians. How­ev­er, the doc­tor pre­sent­ing this infor­ma­tion seemed extreme­ly excit­ed about it.”

As Gup­ta explains the case and cure in ques­tion, a 40-year-old Amer­i­can work­ing in Berlin had been HIV-pos­i­tive for 10 years. The patient’s HIV infec­tion had been under con­trol for four years with “con­ven­tion­al HAART treat­ment reg­i­men” (High­ly Active Anti-Retro­vi­ral Ther­a­py).

When the patient devel­oped leukemia, how­ev­er, a bone mar­row trans­plant of stem cells was done using stan­dard pro­to­col, which Gup­ta said includes radi­a­tion ther­a­py and chemother­a­py pri­or to the trans­plant.

“Remem­ber, once you stop HIV drugs, the HIV viral count ris­es very rapid­ly, usu­al­ly with­in a few days to a week,” Gup­ta said.

Accord­ing to Gup­ta, Huet­ter, the Ger­man physi­cian treat­ing the Amer­i­can, delib­er­ate­ly chose a stem cell donor who had a gene muta­tion known as “CCR‑5 Delta- 32,” rather than using the best matched donor.

Gup­ta said Huet­ter remem­bered research first observed in 1996 — research Gup­ta said is well known in the sci­en­tif­ic com­mu­ni­ty. That research found that cer­tain gay men in the San Fran­cis­co area remained unin­fect­ed with HIV in spite of engag­ing in risky sex­u­al activ­i­ties. As it was lat­er dis­cov­ered, those men had the CCR‑5 Delta-32 gene muta­tion.

As it turned out, the patient’s stem cell trans­plant was a suc­cess, Gup­ta said, even though the patient had to have a sec­ond stem cell trans­plant (from the same donor) when his leukemia relapsed.

“This patient has been off all his HIV drugs for two years now,” Gup­ta said. “He con­tin­ues to show no detectable signs of HIV in all the known places HIV is detect­ed — no signs of HIV in his blood, bone mar­row, lymph nodes, intestines or brain.” Also, the patient’s T‑cell count remains nor­mal.

Thus, accord­ing to Gup­ta, with­in the lim­its of sci­en­tists’ abil­i­ty to detect HIV, it appears this patient’s HIV has been “erad­i­cat­ed.”. . .

14d. The dev­as­tat­ing impli­ca­tions of the find­ings dis­cussed above were elo­quent­ly pre­sent­ed in an online edi­to­r­i­al:

“Aryan Genes Immune to Death from AIDS” by geminiwalker_ink. (This post appears to have dis­ap­peared from the inter­net)

This is the night­mare of AIDS no one wants to believe. As we come clos­er to cel­e­brat­ing, on Decem­ber 1, yet anoth­er World AIDS Day, let’s take a good hard look at what’s real­ly going on before we pour more of our ever dimin­ish­ing hard earned mon­ey down yet anoth­er hor­ren­dous sink­hole. It has been found that some Cau­casians who have test­ed pos­i­tive for the HIV virus were found to take a very long time to actu­al­ly devel­op ‘full-blown’ AIDS (as they call it). It has since been dis­cov­ered (since 1997) that 20% of Euro­pean Cau­casians have the so-called ‘Aryan’ genet­ic dis­po­si­tion. If both your par­ents, in oth­er words, are of Aryan descent, it appears you can nev­er die of AIDS even though you might be infect­ed.

The rea­son for this is in the genet­ic cod­ing of the killer T‑cells, which are part of the body’s immune sys­tem pro­tec­tive shield. These are the cells that are attacked by the HIV retro­virus. The loca­tion of the attack has been dis­cov­ered. It is on the CCR5 gene in the 3rd DNA gene pair. The par­tic­u­lar loca­tion is the Delta 32 RECEPTOR SITE. If either of your DNA pairs (from either your moth­er or your father) is DELTA 32 POSITIVE then the HIV virus can attach itself at that point. If you are DELTA 32 NEGATIVE then HIV just floats around in your blood harm­less­ly for you.

But even though you may be DELTA 32 NEGATIVE at both sites, you can sup­pos­ed­ly still spread the virus. What has been dis­cov­ered is that these 20% of Euro­pean Cau­casians are mem­bers of the Aryan gene pool. Also it has been dis­cov­ered that the far­ther north you go in Europe, say in Nor­way, Fin­land, Swe­den, etc., you find the high­est per­cent­age of peo­ple that are DELTA 32 NEGATIVE at the CCR5 gene allele.

That this would be a sim­ple coin­ci­dence is beyond all human rea­son. To say that HIV sud­den­ly crawled out of the wood­work in Cen­tral Africa by some­one being bit­ten by a green tree mon­key is one thing. But then to say that the only human gene pool on Earth that is immune to HIV is the Aryan Race is a coin­ci­dence that even Howdy Doo­dy wouldn’t buy. . . .

15a. Look­ing ahead to what fig­ures to be a very, very dark future, we feel com­pelled to revis­it some key aspects of the AIDS epi­dem­ic, in light of the alarm­ing pro­lif­er­a­tion of genet­i­cal­ly-mod­i­fied organ­isms. Human­i­ty has failed bad­ly in its approach to the dis­ease, ignor­ing the evi­dence that it was delib­er­ate­ly cre­at­ed.

In FTR #606, we encap­su­lat­ed infor­ma­tion about AIDS [24] col­lat­ed over more than a quar­ter of a cen­tu­ry, dove­tail­ing that with indi­ca­tions that the boil­er-plate research on the dis­ease may track back to the Third Reich and its min­ions hired by the U.S. under Project Paper­clip. We sup­ple­ment­ed this in FTR #682 [25].

In that pro­gram, we made a num­ber of key points that should be revis­it­ed in the con­text of genet­i­cal­ly-mod­i­fied organ­isms and their rapid pro­lif­er­a­tion:

 “Top US Health­care Giant: GMOs Are Dev­as­tat­ing Health” by Antho­ny Guc­cia­r­di [Nat­u­ral­So­ci­ety]; Read­er Sup­port­ed News; 11/28/2012. [32]

Just days after a lead­ing genet­i­cal­ly mod­i­fied organ­ism (GMO) researcher spoke out against GMOs and how many pro-GMO ‘sci­en­tists’ are in bed with Mon­san­to or car­ry their own GMO patents, the largest man­aged health­care provider in the Unit­ed States is now pub­licly speak­ing out against GMOs. In a recent newslet­ter, the Kaiser Per­ma­nente com­pa­ny dis­cussed the numer­ous dan­gers of GMOs in a recent newslet­ter and how to avoid them.

Explain­ing how GM ingre­di­ents have been linked to tumors and organ dam­age in rats in the only life­long rat study avail­able, the newslet­ter high­light­ed how the only real long- term research indi­cates that GMOs are a seri­ous health dan­ger. The newslet­ter, which you can view here, states:

“Despite what the biotech indus­try might say, there is lit­tle research on the long-term effects of GMOs on human health. Inde­pen­dent research has found sev­er­al vari­eties of GMO corn caused organ dam­age in rats. Oth­er stud­ies have found that GMOs may lead to an inabil­i­ty in ani­mals to repro­duce.” . . . .

15b. An overview of Jorge Paulo Leman­n’s busi­ness under­tak­ings, not­ing as we go his Ger­man­ic last name and the pro­found Bor­mann pres­ence in Latin Amer­i­ca and Switzer­land (Leman­n’s place of res­i­dence):

“Jorge Paulo Lemann”; Forbes; 5/27/2016. [16]

Jorge Paulo Lemann is Brazil’s rich­est man thanks to his stake in Anheuser-Busch InBev, the world’s largest brew­er, which he owns through pri­vate equi­ty firm 3G Cap­i­tal togeth­er with fel­low bil­lion­aires and long­time part­ners Car­los Sicu­pi­ra and Mar­cel Her­rmann Telles [a nice Iber­ian name, no?–D.E.]. The trio also has stakes in Restau­rant Brands Inter­na­tion­al, which owns Burg­er King and Tim Hor­tons and is list­ed both the New York and Toron­to stock exchanges. In 2013 Leman­n’s pri­vate equi­ty firm bought H.J. Heinz & Com­pa­ny for $23 bil­lion togeth­er with War­ren Buf­fet­t’s Berk­shire Hath­away. It was 3G Cap­i­tal’s sec­ond acqui­si­tion of an Amer­i­can name brand. In 2010, 3G Cap­i­tal bought Burg­er King in a lever­aged buy­out.